Bristol Myers Squibb Co – ‘10-K’ for 12/31/98 – EX-99

As of:  Tuesday, 3/30/99   ·   For:  12/31/98   ·   Accession #:  14272-99-2   ·   File #:  1-01136

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Form 10-K Fiscal Year Ended December 31, 1998         75    290K 
 2: EX-10.A     Material Contract                                     15     78K 
 3: EX-10.C     Material Contract                                     11     63K 
 4: EX-10.M     Material Contract                                      5     23K 
 5: EX-10.P     Material Contract                                      2     11K 
 6: EX-21       Subsidiaries of the Registrant                         7     28K 
 7: EX-23       Consent of Experts or Counsel                          1      7K 
 8: EX-27       Financial Data Schedule (Pre-XBRL)                     1      8K 
 9: EX-99       Miscellaneous Exhibit                                  1      8K 

EX-99   —   Miscellaneous Exhibit

                                                      EXHIBIT 99.1
                                                      ------------

Cautionary statement regarding forward looking statements made by the Company,  
intended to have the benefit of the "safe harbor" provisions of the Private     
Securities Litigation Reform Act of 1995.                                       

The Company is hereby filing a cautionary statement identifying important       
factors that could cause the Company's actual results to differ materially      
from those projected in forward looking statements made by or on behalf of      
the Company.  There are several communications made by or on behalf of the      
Company (including the Company's Annual Report to Stockholders and Form 10-K)   
which contain statements relating to goals, plans and projections regarding     
its financial position, results of operations, market position and product      
development, among other things, which are based on current expectations that   
involve inherit risks and uncertainties including factors that would delay,     
divert or change one of them in the next several years.                         

These important factors include --                                              

New government laws and regulations, such as (i) health care initiatives,       
(ii) changes in the FDA and foreign regulatory approval processes which         
may cause delays in approving new products, (iii) tax changes such as the       
phasing out of tax benefits heretofore available in the United States and       
certain foreign countries.                                                      

Difficulties in developing new products; new products developed by competitors  
which have lower prices or superior performance features or which are           
otherwise competitive with the Company's current products; and generic          
competition as the Company's products go off patent, as well as possible        
problems with licensors.                                                        

Legal difficulties including negative results relating to patents; adverse      
decisions in litigation including the breast implant cases and other product    
liability cases; the inability to obtain adequate insurance with respect to     
this type of liability; recalls of pharmaceutical products or forced closings   
of manufacturing plants.                                                        

Increasing pricing pressures worldwide from managed care buyers and             
institutional and governmental purchasers; the impact of Year 2000 problems;    
and changes of business and economic conditions including, but not limited to,  
changes in interest rates and fluctuation of foreign currency exchange rates.   

No assurance can be given that any goal or plan set forth in forward looking    
statements can be achieved and readers are cautioned not to place undue         
reliance on such statements, which speak only as of the date made.  The         
Company undertakes no obligation to release publicly any revisions to forward   
looking statements as a result of future events or developments.                

E-8-1               

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/10/21  Bristol-Myers Squibb Co.          10-K       12/31/20  143:28M